Looking to read the full article? Subscribe to BioWorld.

AVEO Signs Potential $477M Schering-Plough Collaboration

April 5, 2007

Cancer drug company AVEO Pharmaceuticals Inc. is partnering a preclinical antibody program with Schering-Plough Corp. for worldwide development and commercialization in a deal that could be worth up to $477.5 million. (BioWorld Today)

BioWorld

Already a subscriber? Sign in

Today's news in brief

BioWorld

BioWorld briefs for Nov. 20.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for Nov. 20.

Desperately seeking wellness and immunity in a sea of COVID-19 research

BioWorld

October brought another burgeoning swell of pandemic news with the U.S. granting its first FDA approval for a COVID-19 therapy, a promising vaccine candidate...

Lucira Health wins FDA nod for first completely in-home COVID-19 test

BioWorld MedTech

Lucira Health Inc. has secured U.S. FDA emergency use authorization for the first prescription molecular diagnostic test for COVID-19 that can be performed from...

Serine deprivation spurs selective translation in pancreatic cancer

BioWorld

One of the reasons that pancreatic cancer remains such a stubbornly dismal disease is that it is extremely desmoplastic. In other words, most of a pancreatic...